| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Women |
| Source | Contemporary OB/GYN |
| URL | contemporaryobgyn.net/view/julia-ordway-on-consequence-of-hormone-supplementation-in-a-postmenopausal-woman (opens in a new tab) |
Specific Claim Evaluated
A postmenopausal woman who received 16 testosterone pellets over 4 years at an anti-aging clinic required a 2-year recovery period.
Primary Research Supporting or Contradicting the Claim
The consensus statement advises against any testosterone preparation that produces supraphysiological concentrations, including pellets and injections (Davis et al., 2019).
Corrected Evidence-Based Interpretation
Accurate as a case report. A single case illustrates a potential harm but cannot estimate its frequency.
Rationale for Grade
The item is clearly identified as a poster presentation of a single case and does not generalize beyond it. The concern it raises is consistent with consensus guidance on pellet therapy. The format is appropriate for a professional audience.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."